Patents by Inventor Wenqing Yao

Wenqing Yao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250115134
    Abstract: An economical optimization strategy construction method and system for lateral stability control of an electric vehicle, and a computer-readable storage medium are provided. The method includes: firstly constructing a lateral stability control system model with active allocation optimization to achieve the coordinational allocation between effective working areas of each part by means of a coordinational variable L; secondly, on the basis of the system model with active allocation optimization, designing a lateral stability controller under a model predictive control framework, where the designed objective function J makes the motion state of the vehicle track the expected value at steady state; and finally, considering the mapping relationship between the additional yaw moment and the coordinational variable L, constructing a three-dimensional surface, and analyzing the influence of the coordinational variable L, and determining the workflow of a regulator of the coordinational variable L.
    Type: Application
    Filed: July 29, 2022
    Publication date: April 10, 2025
    Applicants: CHANGZHOU INSTITUTE OF TECHNOLOGY, JIANGSU UNIVERSITY, ANHUI UNIVERSITY
    Inventors: Jianfeng CHEN, Yicai YE, Chuanye TANG, Jingbo ZHAO, Qiang WU, Weiqi ZHOU, Wenqing YAO, Wen SUN
  • Publication number: 20250084104
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: November 18, 2024
    Publication date: March 13, 2025
    Inventors: Liangxing Wu, Kaijiong Xiao, Wenqing Yao
  • Patent number: 12247026
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: March 11, 2025
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Jingwei Li, Wenqing Yao
  • Patent number: 12247038
    Abstract: The present disclosure is directed to compounds of Formula (I): which modulate PD-1/PD-L1 protein/protein interaction, compositions, and methods of treating various diseases, including infectious diseases and cancer.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: March 11, 2025
    Assignee: Incyte Corporation
    Inventors: Jingwei Li, Liangxing Wu, Wenqing Yao
  • Publication number: 20250057852
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: July 18, 2024
    Publication date: February 20, 2025
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
  • Publication number: 20250059293
    Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.
    Type: Application
    Filed: July 10, 2024
    Publication date: February 20, 2025
    Inventors: Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane, Hui Wang, Yingnan Chen, Xiaozhao Wang, Peter Niels Carlsen, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu, Taisheng Huang
  • Publication number: 20250041310
    Abstract: The present application provides methods of treating cancer using a combination of an inhibitor of A2A and/or A2B and an inhibitor of PD-1 and/or PD-L1.
    Type: Application
    Filed: July 10, 2024
    Publication date: February 6, 2025
    Inventors: Hui Wang, Peter Niels Carlsen, Taisheng Huang, Yong Li, Luping Lin, Chao Qi, Pramod Unnikrishnan Thekkat, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Wenyu Zhu
  • Publication number: 20250034153
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: June 27, 2024
    Publication date: January 30, 2025
    Inventors: Heeoon Han, Le Zhao, Wenqing Yao, Xiaozhao Wang
  • Patent number: 12201636
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: October 3, 2023
    Date of Patent: January 21, 2025
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Joseph Glenn, Thomas P. Maduskuie, Jr., Chunhong He
  • Patent number: 12187743
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: January 7, 2025
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Kaijiong Xiao, Wenqing Yao
  • Patent number: 12187725
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: August 24, 2023
    Date of Patent: January 7, 2025
    Assignee: Incyte Corporation
    Inventors: Yanran Ai, Yu Bai, Joseph Barbosa, Hao Feng, Leah C. Konkol, Xun Liu, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Publication number: 20240400557
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: May 28, 2024
    Publication date: December 5, 2024
    Inventors: Wenyu ZHU, Xiaozhao Wang, Wenqing Yao
  • Publication number: 20240383889
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: December 19, 2023
    Publication date: November 21, 2024
    Inventors: Kai Liu, Jun Pan, Alexander Sokolsky, Oleg Vechorkin, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • Publication number: 20240368152
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: February 9, 2024
    Publication date: November 7, 2024
    Inventors: Qinda YE, Matthew MCCAMMANT, Rocco POLICARPO, Artem SHVARTSBART, Wenyu ZHU, Jeremy ROACH, Gia HOANG, Bin HU, Gencheng LI, Robert SUSICK, Padmaja POLAM, Fenglei ZHANG, Chao QI, Xiaozhao WANG, Wenqing YAO, Alexander Sokolsky, Haolin YIN, Le ZHAO, Peter Carlsen
  • Publication number: 20240360140
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: March 28, 2024
    Publication date: October 31, 2024
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Wenyu Zhu
  • Patent number: 12129267
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: October 29, 2024
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
  • Patent number: 12122767
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: October 22, 2024
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Hai Fen Ye, Wenqing Yao
  • Publication number: 20240343742
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: April 23, 2024
    Publication date: October 17, 2024
    Inventors: Peter Carlsen, Xiaozhao Wang, Alexander Sokolsky, Pei Gan, Rocco Policarpo, Wenqing Yao
  • Publication number: 20240309008
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Application
    Filed: May 22, 2024
    Publication date: September 19, 2024
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • Patent number: 12084449
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: September 10, 2024
    Assignees: INCYTE HOLDINGS CORPORATION, INCYTE CORPORATION
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao